Literature DB >> 311678

Cancer immunotherapy.

R E Falk.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 311678      PMCID: PMC1819004     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Hapten-specific IgE antibody responses in mice. VI. Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide.

Authors:  N Chiorazzi; D A Fox; D H Katz
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

2.  Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.

Authors:  S Fujimoto; M I Greene; A H Sehon
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

3.  Effective antitumor immunity following elimination of suppressor T cell function.

Authors:  R E Falk; N A Nossal; J A Falk
Journal:  Surgery       Date:  1978-10       Impact factor: 3.982

4.  Increased resistance to established tumor metastases after elimination of thymus - T-cell mediated suppression.

Authors:  R E Falk; N Nossal; E S Samuel; J A Falk
Journal:  Surg Forum       Date:  1977

5.  Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma.

Authors:  A Yu; H Watts; N Jaffe; R Parkman
Journal:  N Engl J Med       Date:  1977-07-21       Impact factor: 91.245

6.  Suppressor cell regulation of immune response to tumors: abrogation by adult thymectomy.

Authors:  C L Reinisch; S L Andrew; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

7.  Characterization of suppressor cells in mice bearing syngeneic mastocytoma.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

8.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.